NCT00582985View on ClinicalTrials.gov

Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
CancerNeoplasm Metastasis
Interventions
DRUG

TRC105 chimeric anti-CD105 antibody

TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.

Trial Locations (4)

14263

Buffalo

27705

Durham

85260

Scottsdale

90404

Santa Monica

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT00582985 - Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer | Biotech Hunter | Biotech Hunter